𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Withdrawal of pioglitazone in patients with type 2 diabetes mellitus

✍ Scribed by M. Iwase; T. Asano; N. Sasaki; H. Yoshizumi; S. Hiramatsu; Y. Sakai; A. Ogo; M. Iida

Book ID
108849310
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
225 KB
Volume
35
Category
Article
ISSN
0269-4727

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Pioglitazone for patients with type 2 di
Pioglitazone for patients with type 2 diabetes and nonalcoholic steatohepatitis
✍ Janet King; Kris V. Kowdley πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 73 KB

Background: No pharmacologic therapy has conclusively proved to be effective for the treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance, steatosis, and necroinflammation with or without centrilobular fibrosis. Pioglitazone is a thiazolidinedione that ameliorates

Withdrawal of insulin therapy after adju
Withdrawal of insulin therapy after adjunctive treatment with acarbose in a patient with Type 2 diabetes mellitus
✍ Bennett, SMA ;Stewart, MW πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 269 KB

## Abstract Acarbose has been shown to reduce post‐prandial hyperglycaemia and improve glycaemic control in patients with Type 2 diabetes mellitus. We report its use as an adjunct to established insulin therapy in a 64 year old man with Type 2 diabetes mellitus and secondary failure to treatment wi